Trials / NCT06162585
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Underway, not enrolling Observational Natural history / observational
- Sponsor
- Nanoscope Therapeutics Inc.
- Treatment
- Gene Therapy product-MCO-010
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
- Ages
- 18 Years to no upper limit
- Enrollment
- 18 participants
- Started
- 2023-12-08
- Main results expected
- 2027-07
- Results posted
- Not yet
- Record last updated
- 2025-03-24
What the study is testing
This study will be conducted following Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines. Eligible subjects will be consented to return for scheduled study visits for this study following their completion in study NTXMCO-002 (RESTORE). They will not receive a second treatment with MCO-010 (or a repeated sham injection) in this study
Where it runs
Puerto Rico (1)
- Nanoscope Clinical Site, Arecibo
United States (5)
- Nanoscope Clinical Site, Beverly Hills, California
- Nanoscope Clinical Site, Pensacola, Florida
- Nanoscope Clinical Site, Fargo, North Dakota
- Nanoscope Clinical Site, Houston, Texas
- Nanoscope Clinical Site, McAllen, Texas